Literature DB >> 1458765

Lack of pharmacokinetic interactions between moxonidine and digoxin.

G Pabst1, H J Weimann, W Weber.   

Abstract

The potential for pharmacokinetic interactions between moxonidine and digoxin at steady-state was investigated in 15 healthy male volunteers. Multiple oral doses of 0.2mg moxonidine twice daily and 0.2mg digoxin once daily were administered alone and in combination in a randomised 3-period crossover design. The drugs were administered for at least 5 days. The results indicate that neither moxonidine nor digoxin influences the pharmacokinetics of the other drug under steady-state conditions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458765     DOI: 10.2165/00003088-199223060-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

1.  [Long-term experiences with moxonidine, a new antihypertensive agent].

Authors:  W Schwarz; J Kandziora
Journal:  Fortschr Med       Date:  1990-11-10

2.  Lack of pharmacokinetic interaction as an equivalence problem.

Authors:  V W Steinijans; M Hartmann; R Huber; H W Radtke
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-08

3.  Confidence intervals rather than P values: estimation rather than hypothesis testing.

Authors:  M J Gardner; D G Altman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-15

4.  Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers.

Authors:  D Trenk; F Wagner; E Jähnchen; V Plänitz
Journal:  J Clin Pharmacol       Date:  1987-12       Impact factor: 3.126

5.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

6.  On clinically relevant differences and shifted null hypotheses.

Authors:  N Victor
Journal:  Methods Inf Med       Date:  1987-07       Impact factor: 2.176

7.  The influence of renal function on clinical pharmacokinetics of moxonidine.

Authors:  W Kirch; H J Hutt; V Plänitz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

8.  Unique presynaptic alpha 2-receptor selectivity and specificity of the antihypertensive agent moxonidine.

Authors:  B I Armah
Journal:  Arzneimittelforschung       Date:  1988-10

9.  Absolute bioavailability of moxonidine.

Authors:  R Theodor; H J Weimann; W Weber; K Michaelis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Apr-Jun       Impact factor: 2.441

  9 in total
  1 in total

Review 1.  Safety and tolerability of moxonidine in the treatment of hypertension.

Authors:  M Schachter; J Luszick; B Jäger; C Verboom; E Söhlke
Journal:  Drug Saf       Date:  1998-09       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.